ERBB2 and breast carcinoma: Genetically modified DCs generated via recombinant adenoviral transduction of bone marrow-derived DCs to express a truncated HER2 protein were developed and tested in vivo. The vaccine increased the production of anti-HER2 antibodies, enhanced T cell response, and delayed the onset of mammary carcinomas in mice 110.